Affiliation:
1. Department of Medical Microbiology, Faculty of Medicine, University of Manitoba
2. Departments of Medicine
3. Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba
4. Mount Sinai Hospital, Toronto, Ontario, Canada
Abstract
ABSTRACT
A total of 6,991 unique patient isolates of
Streptococcus pneumoniae
were collected from October 1997 to June 2002 from 25 medical centers in 9 of the 10 Canadian provinces. Among these isolates, 20.2% were penicillin nonsusceptible, with 14.6% being penicillin intermediate (MIC, 0.12 to 1 μg/ml) and 5.6% being penicillin resistant (MIC, ≥2 μg/ml). The proportion of high-level penicillin-resistant
S. pneumoniae
isolates increased from 2.4 to 13.8% over the last 3 years of the study, and the proportion of multidrug-resistant
S. pneumoniae
isolates increased from 2.7 to 8.8% over the 5-year period. Resistant rates (intermediate and resistant) among non-β-lactam agents were as follows: macrolides, 9.6 to 9.9%; clindamycin, 3.8%; doxycycline, 5.5%; chloramphenicol, 3.9%; and trimethoprim-sulfamethoxazole, 19.0%. Rates of resistance to non-β-lactam agents were higher among penicillin-resistant strains than among penicillin-susceptible strains. No resistance to vancomycin or linezolid was observed; however, 0.1% intermediate resistance to quinupristin-dalfopristin was observed. The rate of macrolide resistance (intermediate and resistant) increased from 7.9 to 11.1% over the 5 years. For the fluoroquinolones, the order of activity based on the MICs at which 50% of isolates are inhibited (MIC
50
s) and the MIC
90
s was gemifloxacin > clinafloxacin > trovafloxacin > moxifloxacin > grepafloxacin > gatifloxacin > levofloxacin > ciprofloxacin. The investigational compounds ABT-773 (MIC
90
, 0.008 μg/ml), ABT-492 (MIC
90
, 0.015 μg/ml), GAR-936 (tigecycline; MIC
90
, 0.06 μg/ml), and BMS284756 (garenoxacin; MIC
90
, 0.06 μg/ml) displayed excellent activities. Despite decreases in the rates of antibiotic consumption in Canada over the 5-year period, the rates of both high-level penicillin-resistant and multidrug-resistant
S. pneumoniae
isolates are increasing in Canada.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference40 articles.
1. Appelbaum, P. C. 1997. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis.15:77-83.
2. Ball P. 1999. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am. J. Med. 107 (Suppl. 1A) : 77S-85S.
3. Barcus, V. A., K. Ghanekar, M. Yeo, T. J. Coffey, and C. G. Dowson. 1995. Genetics of high-level penicillin resistance in clinical isolates of Streptococcus pneumoniae. FEMS Microbiol. Lett.126:299-304.
4. Barry, A. L., S. D. Brown, and P. C. Fuchs. 1999. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother.43:428-429.
5. Bartlett, J. G., R. F. Breiman, L. A. Mandell, and T. M. File, Jr. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis.26:811-838.
Cited by
140 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献